TY - JOUR
T1 - Variation in Number of Doses, Bottle Volume, and Calculated Yearly Cost of Generic and Branded Latanoprost for Glaucoma
AU - Queen, Joanna H.
AU - Feldman, Robert M.
AU - Lee, David A.
N1 - Funding Information:
Funding/Support: This study was supported the Hermann Eye Fund (Houston, Texas, USA), National Eye Institute (Bethesda, Maryland, USA) Vision Core Grant P30EY010608, and a Challenge Grant to The University of Texas Medical School at Houston (Houston, Texas, USA) from Research to Prevent Blindness (New York, New York, USA). Financial disclosures: Dr Feldman is a member of the Alcon Speakers Bureau (Fort Worth, Texas, USA) and has received research funding from Alcon and from Pfizer (New York, New York, USA). Dr Feldman is also a consultant for Alcon. Dr Lee has also received research funding from Alcon. Alcon (Fort Worth, Texas, USA) and Sandoz (Princeton, New Jersey, USA) are both owned by Novartis (Basel, Switzerland). The following author has no financial disclosures: Joanna H. Queen. All authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2016 Elsevier Inc. All rights reserved.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Purpose To evaluate discrepancies in doses per bottle, bottle fill volume, and cost among branded and generic formulations of latanoprost. Design Comparative economic analysis. Methods This study was conducted at the Ruiz Department of Ophthalmology and Visual Science at The University of Texas Health Science Center at Houston (UTHealth). Four regionally available latanoprost formulations were measured. Number of drops per bottle and actual bottle fill volume were measured for a calculated sample size (10 bottles). Annual cost (using average wholesale price), days use per bottle, drops per milliliter, and number of bottles used per year were calculated. Data were summarized using mean and standard deviation; 1-way analysis of variance and post hoc Tukey's studentized range test were used for comparing means among manufacturers. Results Pfizer's branded lantanoprost, Xalatan (New York, New York, USA), had the largest fill volume (P <.001). Pfizer had the highest yearly cost at $1198 (P <.001), whereas Akorn (Lake Forest, Illinois, USA) and Bausch & Lomb (Rochester, New York, USA) had the lowest ($184 and $201, respectively). Pfizer and Bausch & Lomb had the most drops per bottle (87.3 and 88.7, respectively), which was statistically more (P <.001) than either Akorn or Sandoz (Princeton, New Jersey, USA) (77.6 and 76.6, respectively), but there was no statistical difference among the standard deviation of drops per bottle (Levene 0.14). Conclusions Annual cost and number of doses per bottle, factors important to patients, vary significantly depending on the manufacturer of latanoprost. Practitioners can better advise patients by being aware of these differences.
AB - Purpose To evaluate discrepancies in doses per bottle, bottle fill volume, and cost among branded and generic formulations of latanoprost. Design Comparative economic analysis. Methods This study was conducted at the Ruiz Department of Ophthalmology and Visual Science at The University of Texas Health Science Center at Houston (UTHealth). Four regionally available latanoprost formulations were measured. Number of drops per bottle and actual bottle fill volume were measured for a calculated sample size (10 bottles). Annual cost (using average wholesale price), days use per bottle, drops per milliliter, and number of bottles used per year were calculated. Data were summarized using mean and standard deviation; 1-way analysis of variance and post hoc Tukey's studentized range test were used for comparing means among manufacturers. Results Pfizer's branded lantanoprost, Xalatan (New York, New York, USA), had the largest fill volume (P <.001). Pfizer had the highest yearly cost at $1198 (P <.001), whereas Akorn (Lake Forest, Illinois, USA) and Bausch & Lomb (Rochester, New York, USA) had the lowest ($184 and $201, respectively). Pfizer and Bausch & Lomb had the most drops per bottle (87.3 and 88.7, respectively), which was statistically more (P <.001) than either Akorn or Sandoz (Princeton, New Jersey, USA) (77.6 and 76.6, respectively), but there was no statistical difference among the standard deviation of drops per bottle (Levene 0.14). Conclusions Annual cost and number of doses per bottle, factors important to patients, vary significantly depending on the manufacturer of latanoprost. Practitioners can better advise patients by being aware of these differences.
UR - http://www.scopus.com/inward/record.url?scp=84959228794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959228794&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2015.11.021
DO - 10.1016/j.ajo.2015.11.021
M3 - Article
C2 - 26596398
AN - SCOPUS:84959228794
VL - 163
SP - 70-74.e1
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
ER -